N/A N=109 Randomized Quadruple-blind Treatment

Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury

Contrast-induced Acute Kidney Injury

Bottom Line

View on ClinicalTrials.gov: NCT03236441 ↗

Enrolled (actual)

109

Serious AEs

11.0%

Results posted

Jan 2025

Primary outcome: Primary: Number of Patients With Acute Kidney Injury — 8; 16 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: RIPC (Device); Sham-RIPC (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Oladipupo Olafiranye, MD, MS
Primary completion: Feb 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients With Acute Kidney Injury	8; 16	—
SECONDARY The Product of Urinary (Tissue Inhibitor of Metalloproteinases 2) X (Insulin-like Growth Factor-binding Protein 7)	0.39; 0.51; 0.71; .49; 0.67; 0.67	—
SECONDARY Number of Patients With Major Adverse Cardiovascular and Cerebrovascular Event	9; 20	—
SECONDARY Number of Patients With Major Adverse Kidney Event	4; 6	—
SECONDARY Cyclic Guanylate Monophosphate (cGMP) Level	60.12; 55.19; 68.28; 59.66; 62.91; 55.22	—

Summary

This a prospective, double-blind, sham-controlled, randomized clinical trial to study the effects of remote ischemic preconditioning on acute kidney injury, vascular and renal biomarkers in patients with non-ST elevation myocardial infarction and unstable angina undergoing coronary angiography and/or percutaneous coronary intervention.

Eligibility Criteria

Inclusion Criteria

Patient with non-ST elevation myocardial infarction or unstable angina
Referral for cardiac catheterization and percutaneous coronary intervention
Contrast-induced acute kidney injury risk score of ≥11

Exclusion Criteria

Inability to give informed consent
unstable blood pressure (systolic blood pressure > 200 or <90 mmHg)
History of allergy to contrast media
Peripheral vascular disease of upper limb
Renal disease requiring dialysis
Placement of arteriovenous fistula and arteriovenous graft

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03236441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.